ArticleAnnals of hematology2026

Final results of the CARO study: real-world adherence, effectiveness and patient-reported quality of life with carfilzomib-based regimens in German patients with relapsed/refractory multiple myeloma.

Karin Potthoff et al.PubMed ↗Publisher ↗

No numbers read from the abstract.